Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | GRM5 | P41594 | 3/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18427396 | 0.81 | SMN1; SMN2 (0.38) | LMNAKDM4E | |
| SCHEMBL19646227 | 0.81 | SMN1; SMN2 (0.38) | LMNAKDM4E | |
| SCHEMBL21450061 | 0.77 | ESR1 (0.39) | ESR1ESR2 | |
| SCHEMBL19002008 | 0.77 | ALDH1A1 (0.32) | ESR1ESR2 | |
| SCHEMBL23558267 | 0.76 | SLC6A2 (0.35) | ESR1ESR2GRM5 | |
| SCHEMBL22166482 | 0.76 | RXRA (0.34) | LMNAKDM4E | |
| SCHEMBL21250118 | 0.74 | SCN8A (0.34) | HRH1CXCR4KDM4E | |
| SCHEMBL2609293 | 0.72 | GABRA1 (0.38) | ESR1KDM4EUSP2HPGDHSD17B10 | |
| SCHEMBL19186163 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL23790646 | 0.71 | CXCR4 (0.36) | MEN1KMT2AHRH1CXCR4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186579-B2 | Therapeutic heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11186579-B2 | Therapeutic heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | ESR1 4303/4885ESR2 3516/4885MEN1 381/4885 |
| US-20200031834-A1 | THERAPEUTIC HETEROCYCLIC COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MAPT, SLC10A1 | ESR1 4303/4885ESR2 3516/4885MEN1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.